nifedipine has been researched along with Pre-Eclampsia in 102 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Pre-Eclampsia: A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Giant PANDA study is a pragmatic, open-label, multicentre, randomised controlled trial of a treatment initiation strategy with nifedipine (calcium channel blocker), versus labetalol (mixed alpha/beta blocker) in 2300 women with pregnancy hypertension." | 9.69 | A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA). ( Ashworth, D; Battersby, C; Bick, D; Chappell, LC; Green, M; Hardy, P; Leighton, L; Magee, LA; Maher, A; McManus, RJ; Moakes, C; Morris, RK; Myers, J; Nelson-Piercy, C; Rivero-Arias, O; Sparkes, J; Webb, A; Wilson, H, 2023) |
| "Oral nifedipine is commonly used to treat pre-eclampsia, one of the most severe complications during pregnancy, but its clinical efficacy is less than ideal." | 9.27 | Epigallocatechin gallate enhances treatment efficacy of oral nifedipine against pregnancy-induced severe pre-eclampsia: A double-blind, randomized and placebo-controlled clinical study. ( Guo, JJ; Shi, DD; Wang, N; Zhou, L, 2018) |
| "In the present study, the efficacy and safety of oral nifedipine and intravenous labetalol for severe pre-eclampsia therapy were compared." | 9.22 | Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia. ( Shi, DD; Wang, N; Yang, FZ; Zhou, L, 2016) |
| " administration of nitroglycerine as an antihypertensive agent in the management of pre-eclampsia is scarce." | 9.13 | Efficacy of nitroglycerine infusion versus sublingual nifedipine in severe pre-eclampsia: a randomized, triple-blind, controlled trial. ( Gordillo-Moscoso, A; Hernández-Sierra, JF; Mandeville, PB; Manzur-Verástegui, S; Rodríguez-Martínez, M, 2008) |
| "Magnesium sulfate may prevent eclampsia by reducing cerebral vasoconstriction and ischemia." | 9.10 | A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. ( Allen, JC; Anthony, J; Belfort, MA; Saade, GR, 2003) |
| "Nifedipine is safe and more effective than hydralazine in controlling blood pressure in severe pre-eclampsia." | 9.10 | Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia. ( Aali, BS; Nejad, SS, 2002) |
| "To determine whether nifedipine or prazosin is the more appropriate second-line antihypertensive agent in pregnancy." | 9.09 | Nifedipine or prazosin as a second agent to control early severe hypertension in pregnancy: a randomised controlled trial. ( Hall, DR; Odendaal, HJ; Smith, M; Steyn, DW, 2000) |
| "Our purpose was to compare the hemodynamic effects of orally administered nifedipine and intravenously administered labetalol in preeclamptic hypertensive emergencies." | 9.09 | A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies. ( Chauhan, SP; Hogg, BB; Newman, RB; Scardo, JA; Vermillion, ST, 1999) |
| "We sought to compare the efficacies of oral nifedipine and intravenous labetalol in the acute management of hypertensive emergencies of pregnancy." | 9.09 | A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. ( Chauhan, SP; Newman, RB; Scardo, JA; Vermillion, ST, 1999) |
| "To compare the effects of a single oral dose of nifedipine with those of intravenous dihydralazine on central haemodynamics in pregnant women with severe pre-eclampsia." | 9.08 | A comparison between the haemodynamic effects of oral nifedipine and intravenous dihydralazine in patients with severe pre-eclampsia. ( Visser, W; Wallenburg, HC, 1995) |
| "The objective was to compare the fetal and maternal effects between parenteral hydralazine and sublingual nifedipine used like antihypertensive drugs in the management of severe preeclampsia." | 9.07 | [Management of severe pre-eclampsia/eclampsia. Comparison between nifedipine and hydralazine as antihypertensive agents]. ( Flores Padilla, LM; Walss Rodriguez, RJ, 1993) |
| "The therapeutic effect of the calcium antagonist; Nifedipine was assessed in 30 patients with pre-eclampsia." | 9.07 | Evaluation of calcium-antagonist (Nifedipine) in the treatment of pre-eclampsia. ( Ismail, AA; Kholeif, A; Medhat, I; Tawfic, TA, 1993) |
| "The objective of our study was to test the hypothesis that treatment with nifedipine for mild preeclampsia remote from term reduces the number of days of maternal hospitalization and improves pregnancy outcome." | 9.07 | A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. ( Akl, S; Barton, JR; Mercer, BM; Sarinoglu, C; Sibai, BM, 1992) |
| "Tradiational drug therapy choices for hypertension in pregnancy continue to be hydralazine for acute reduction of blood pressure and methyldopa for the management of chronic hypertension." | 8.79 | Use of nifedipine in the hypertensive diseases of pregnancy. ( Doering, PL; Hatton, RC; Levin, AC, 1994) |
| "To investigate the effect of 7 to 14 days of therapy with nifedipine (sustained-release preparation) on the 24-hour blood pressure patterns of pregnant women with pre-eclampsia or chronic hypertension, and to test the utility of blood pressure monitoring in modulating the timing and dosage of the drug." | 7.69 | 24-hour blood pressure monitoring to evaluate the effects of nifedipine in pre-eclampsia and in chronic hypertension in pregnancy. ( Benedetto, C; Carandente, F; Chiarolini, L; Giarola, M; Maulà, V; Zonca, M, 1997) |
| "Our purpose was to evaluate the hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies." | 7.69 | Hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies. ( Hogg, BB; Newman, RB; Scardo, JA; Vermillion, ST, 1996) |
| "Nifedipine was administered to 49 pregnant women with gestational hypertension as first-line therapy, and were longitudinally studied as paired observations for 3 or 10 day intervals of treatment with nifedipine until delivery." | 7.69 | The use of nifedipine as first-line hypotensive therapy in gestational hypertension. ( Caruso, A; De Carolis, MP; De Carolis, S; Ferrazzani, S; Mancinelli, S; Romano, D, 1994) |
| "To study the effects of nifedipine on the microcirculation in pregnancy-induced hypertension (PIH)." | 7.69 | [The effect of nifedipine on the microcirculation in pregnancy-induced hypertension]. ( Hao, C; Li, F; Yu, X, 1996) |
| "Preeclampsia is associated with maternal and perinatal morbidity." | 7.30 | Trial of Intrapartum Extended-Release Nifedipine to Prevent Severe Hypertension Among Pregnant Individuals With Preeclampsia With Severe Features. ( Cleary, EM; Costantine, MM; Kudrimoti, M; Patton, KG; Racchi, NW; Rood, KM, 2023) |
| " Hence, the data suggest gastroretention as a promising approach to enhance bioavailability of nifedipine." | 6.90 | Formulation, Optimization, and In vivo Evaluation of Gastroretentive Drug Delivery System of Nifedipine for the Treatment of Preeclampsia. ( Avari, JG; Karemore, MN, 2019) |
| "A total of 626 patients with preeclampsia were enrolled, screened, and assigned by random to groups receiving either nifedipine + placebo or nifedipine + celastrol orally." | 6.84 | Celastrol synergizes with oral nifedipine to attenuate hypertension in preeclampsia: a randomized, placebo-controlled, and double blinded trial. ( Liang, Y; Wang, D; Xiao, S; Zhang, M, 2017) |
| "One hundred forty-eight women with mild preeclampsia were randomly allocated to treatment with either bed rest alone (n=64) or in combination with nifedipine (n=84) at 26-36 weeks' gestation." | 6.68 | The effect of nifedipine on urinary excretion of calcium in preeclampsia. ( Barton, JR; Mercer, BM; Sibai, BM, 1997) |
| "The patients with preeclampsia undergoing emergent cesarean section is always a challenge to an anesthesiologist, because severe hypertensive response after laryngoscopy and tracheal intubation may result in life-threatening complication such as cerebral hemorrhage." | 6.67 | [Nifedipine in preeclampsia for cesarean section]. ( Chen, JC; Hong, YJ; Lin, CF; Pan, P; Wei, TT; Wong, KL, 1993) |
| "Nifedipine is a calcium channel blocker that reduces blood pressure and increases renal blood flow." | 6.67 | The use of nifedipine during the postpartum period in patients with severe preeclampsia. ( Barton, JR; Conover, WB; Hiett, AK, 1990) |
| " Therapy success: systolic blood pressure ~140 mm Hg and diastolic blood pressure ~90 mm Hg, therapy failure: persistent systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 110 mm Hg after maximum dosage of therapy (EL)." | 5.91 | Comparison of outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine in 355 pregnant Han Chinese women with preeclampsia. ( Dong, W; Peng, Z; Xiao, Y; Zhang, J, 2023) |
| "The Giant PANDA study is a pragmatic, open-label, multicentre, randomised controlled trial of a treatment initiation strategy with nifedipine (calcium channel blocker), versus labetalol (mixed alpha/beta blocker) in 2300 women with pregnancy hypertension." | 5.69 | A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA). ( Ashworth, D; Battersby, C; Bick, D; Chappell, LC; Green, M; Hardy, P; Leighton, L; Magee, LA; Maher, A; McManus, RJ; Moakes, C; Morris, RK; Myers, J; Nelson-Piercy, C; Rivero-Arias, O; Sparkes, J; Webb, A; Wilson, H, 2023) |
| "To explore the regulatory effect of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia." | 5.56 | Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia. ( Wang, DJ; Wu, Y; Zhang, R; Zhang, Y; Zhang, YX, 2020) |
| "In 14 patients with preeclampsia, 55 hypertensive emergencies were identified (BP >150/95)." | 5.46 | A trial of oral nifedipine and oral labetalol in preeclampsia hypertensive emergency treatment. ( Arjona-Berral, JE; Castelo-Branco, C; Duro-Gómez, J; Duro-Gómez, L; Giménez de Azcárete, M; Hernández-Angeles, C; Rodríguez-Marín, AB, 2017) |
| "Women with preeclampsia have elevated levels of inflammatory cytokines including IL-6." | 5.42 | The reduction of circulating levels of IL-6 in pregnant women with preeclampsia by magnesium sulphate and nifedipine: In vitro evidence for potential mechanisms. ( Chamley, LW; Chen, Q; Guo, F; Stone, PR; Xiao, JP; Yin, YX; Zhao, M, 2015) |
| "Totally 704 preeclampsia patients were randomly assigned to the treatment group and the control group, 352 cases in each group." | 5.42 | [Effect of Magnesium Sulfate, Nifedipine Tablet Combined Salvia Injection on ET-1/NO, TXA2/PGI2 and Hemorheology of Preeclampsia Patients]. ( Li, M; Qiu, SQ; Yao, J; Zhang, M; Zheng, XY; Zhu, JM; Zhu, ZX, 2015) |
| "The cases had more severe preeclampsia and a longer magnesium sulfate infusion." | 5.33 | Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. ( Carleton, B; Cheng, C; Côté, AM; Ensom, MH; Li, J; Magee, LA; Miremadi, S; von Dadelszen, P, 2005) |
| "The use of labetalol and nifedipine were not related to any significant changes in fetal Doppler, which is reassuring about the safety of these drugs when treating acute severe hypertension in pregnancy." | 5.30 | To study the changes in fetal hemodynamics with intravenous labetalol or nifedipine in acute severe hypertension. ( Gainder, S; Prakash, M; Saha, SC; Thakur, M, 2019) |
| "This was a nested cohort study of women with chronic hypertension and a singleton pregnancy recruited to the PANDA (Pregnancy And chronic hypertension: NifeDipine vs lAbetalol as antihypertensive treatment) study at one of three UK maternity units." | 5.30 | Longitudinal changes in vascular function parameters in pregnant women with chronic hypertension and association with adverse outcome: a cohort study. ( Chappell, LC; Cruickshank, JK; Khalil, A; Mills, C; Myers, JE; Nelson-Piercy, C; Seed, PT; Watt-Coote, I; Webster, LM, 2019) |
| "Pharmacokinetic and pharmacodynamic parameters of oral nifedipine were studied in the immediate postpartum period in eight women with preeclampsia." | 5.28 | Nifedipine pharmacokinetics and pharmacodynamics during the immediate postpartum period in patients with preeclampsia. ( Barton, JR; Prevost, RR; Sibai, BM; Whybrew, WD; Wilson, DA, 1991) |
| "Also, patients with superimposed preeclampsia were treated with 40 mg/day oral nifedipine." | 5.28 | Nifedipine treatment in preeclampsia reverts the increased erythrocyte aggregation to normal. ( Boemi, M; De Tommaso, G; Fumelli, P; Garzetti, GG; Lucino, E; Romanini, C; Tranquilli, AL, 1992) |
| "Twenty patients with preeclampsia at a gestational age of 26 to 35 weeks were treated with oral nifedipine until delivery." | 5.28 | The effect of nifedipine therapy on fetal and placental Doppler waveforms in preeclampsia remote from term. ( Akl, S; Fairlie, FM; Khoury, AD; Moretti, MM; Sibai, BM, 1990) |
| "Oral nifedipine is commonly used to treat pre-eclampsia, one of the most severe complications during pregnancy, but its clinical efficacy is less than ideal." | 5.27 | Epigallocatechin gallate enhances treatment efficacy of oral nifedipine against pregnancy-induced severe pre-eclampsia: A double-blind, randomized and placebo-controlled clinical study. ( Guo, JJ; Shi, DD; Wang, N; Zhou, L, 2018) |
| "Two women with preeclampsia treated unsuccessfully with alpha-methyldopa and magnesium sulfate became profoundly hypotensive when oral nifedipine was added." | 5.27 | Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia? ( Cámera, MI; Martinotti, A; Mayorga, LM; Vignolo, CA; Waisman, GD, 1988) |
| "In the present study, the efficacy and safety of oral nifedipine and intravenous labetalol for severe pre-eclampsia therapy were compared." | 5.22 | Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia. ( Shi, DD; Wang, N; Yang, FZ; Zhou, L, 2016) |
| " administration of nitroglycerine as an antihypertensive agent in the management of pre-eclampsia is scarce." | 5.13 | Efficacy of nitroglycerine infusion versus sublingual nifedipine in severe pre-eclampsia: a randomized, triple-blind, controlled trial. ( Gordillo-Moscoso, A; Hernández-Sierra, JF; Mandeville, PB; Manzur-Verástegui, S; Rodríguez-Martínez, M, 2008) |
| "Nifedipine is safe and more effective than hydralazine in controlling blood pressure in severe pre-eclampsia." | 5.10 | Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia. ( Aali, BS; Nejad, SS, 2002) |
| "Magnesium sulfate may prevent eclampsia by reducing cerebral vasoconstriction and ischemia." | 5.10 | A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. ( Allen, JC; Anthony, J; Belfort, MA; Saade, GR, 2003) |
| "We sought to compare the efficacies of oral nifedipine and intravenous labetalol in the acute management of hypertensive emergencies of pregnancy." | 5.09 | A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. ( Chauhan, SP; Newman, RB; Scardo, JA; Vermillion, ST, 1999) |
| "To determine whether nifedipine or prazosin is the more appropriate second-line antihypertensive agent in pregnancy." | 5.09 | Nifedipine or prazosin as a second agent to control early severe hypertension in pregnancy: a randomised controlled trial. ( Hall, DR; Odendaal, HJ; Smith, M; Steyn, DW, 2000) |
| "Our purpose was to compare the hemodynamic effects of orally administered nifedipine and intravenously administered labetalol in preeclamptic hypertensive emergencies." | 5.09 | A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies. ( Chauhan, SP; Hogg, BB; Newman, RB; Scardo, JA; Vermillion, ST, 1999) |
| "To compare the effects of a single oral dose of nifedipine with those of intravenous dihydralazine on central haemodynamics in pregnant women with severe pre-eclampsia." | 5.08 | A comparison between the haemodynamic effects of oral nifedipine and intravenous dihydralazine in patients with severe pre-eclampsia. ( Visser, W; Wallenburg, HC, 1995) |
| "The objective was to compare the fetal and maternal effects between parenteral hydralazine and sublingual nifedipine used like antihypertensive drugs in the management of severe preeclampsia." | 5.07 | [Management of severe pre-eclampsia/eclampsia. Comparison between nifedipine and hydralazine as antihypertensive agents]. ( Flores Padilla, LM; Walss Rodriguez, RJ, 1993) |
| "The therapeutic effect of the calcium antagonist; Nifedipine was assessed in 30 patients with pre-eclampsia." | 5.07 | Evaluation of calcium-antagonist (Nifedipine) in the treatment of pre-eclampsia. ( Ismail, AA; Kholeif, A; Medhat, I; Tawfic, TA, 1993) |
| "The objective of our study was to test the hypothesis that treatment with nifedipine for mild preeclampsia remote from term reduces the number of days of maternal hospitalization and improves pregnancy outcome." | 5.07 | A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. ( Akl, S; Barton, JR; Mercer, BM; Sarinoglu, C; Sibai, BM, 1992) |
| " The incidence of severe hypertension was significantly lower when nifedipine (odds ratio, 0." | 5.05 | Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis. ( Bellos, I; Daskalakis, G; Loutradis, D; Papapanagiotou, A; Pergialiotis, V, 2020) |
| " Oral nifedipine is now considered an alternative first-line therapy, along with intravenous hydralazine and labetalol for women presenting with pre-eclampsia." | 4.98 | Focused Update on Pharmacologic Management of Hypertensive Emergencies. ( Broscious, R; Devabhakthuni, S; Noel, ZR; Watson, K, 2018) |
| "Tradiational drug therapy choices for hypertension in pregnancy continue to be hydralazine for acute reduction of blood pressure and methyldopa for the management of chronic hypertension." | 4.79 | Use of nifedipine in the hypertensive diseases of pregnancy. ( Doering, PL; Hatton, RC; Levin, AC, 1994) |
| " The American College of Obstetricians and Gynecologists recommends that acute-onset, severe hypertension be treated with first line-therapy (intravenous labetalol, intravenous hydralazine or oral nifedipine) within 60 minutes to reduce risk of maternal morbidity and death." | 3.96 | Identification of factors associated with delayed treatment of obstetric hypertensive emergencies. ( Akerman, MB; Elsayad, A; Halpern, TA; Heiselman, CJ; Heo, HJ; Kantorowska, A; Muscat, JC; Sicuranza, GB; Vintzileos, AM, 2020) |
| "These findings demonstrate that agents commonly used for the treatment of hypertensive disease in pregnancy, excluding alpha-methyldopa, have significant direct effects on the feto-placental circulation." | 3.72 | Anti-hypertensive therapy and the feto-placental circulation: effects on umbilical artery resistance. ( Dennedy, MC; Houlihan, DD; Morrison, JJ; Ravikumar, N, 2004) |
| "To study the effects of nifedipine on the microcirculation in pregnancy-induced hypertension (PIH)." | 3.69 | [The effect of nifedipine on the microcirculation in pregnancy-induced hypertension]. ( Hao, C; Li, F; Yu, X, 1996) |
| "Nifedipine was administered to 49 pregnant women with gestational hypertension as first-line therapy, and were longitudinally studied as paired observations for 3 or 10 day intervals of treatment with nifedipine until delivery." | 3.69 | The use of nifedipine as first-line hypotensive therapy in gestational hypertension. ( Caruso, A; De Carolis, MP; De Carolis, S; Ferrazzani, S; Mancinelli, S; Romano, D, 1994) |
| "To investigate the effect of 7 to 14 days of therapy with nifedipine (sustained-release preparation) on the 24-hour blood pressure patterns of pregnant women with pre-eclampsia or chronic hypertension, and to test the utility of blood pressure monitoring in modulating the timing and dosage of the drug." | 3.69 | 24-hour blood pressure monitoring to evaluate the effects of nifedipine in pre-eclampsia and in chronic hypertension in pregnancy. ( Benedetto, C; Carandente, F; Chiarolini, L; Giarola, M; Maulà, V; Zonca, M, 1997) |
| "Our purpose was to evaluate the hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies." | 3.69 | Hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies. ( Hogg, BB; Newman, RB; Scardo, JA; Vermillion, ST, 1996) |
| "Nifedipine has been used to treat hypertension in pregnancy, and does not influence fetal or uteroplacental circulations in patients with preeclampsia." | 3.69 | Changes in blood velocities of fetal circulation in association with fetal heart rate abnormalities: effect of sublingual administration of nifedipine. ( Hata, K; Hata, T; Kitao, M; Manabe, A, 1995) |
| "Preeclampsia is associated with maternal and perinatal morbidity." | 3.30 | Trial of Intrapartum Extended-Release Nifedipine to Prevent Severe Hypertension Among Pregnant Individuals With Preeclampsia With Severe Features. ( Cleary, EM; Costantine, MM; Kudrimoti, M; Patton, KG; Racchi, NW; Rood, KM, 2023) |
| "Hypertension during pregnancy is associated with a higher risk of cardiovascular disease and kidney failure." | 3.01 | Evaluation and Management of Hypertensive Disorders of Pregnancy. ( Bajpai, D; Dumanski, S; Popa, C; Shah, S; Verma, P, 2023) |
| " Hence, the data suggest gastroretention as a promising approach to enhance bioavailability of nifedipine." | 2.90 | Formulation, Optimization, and In vivo Evaluation of Gastroretentive Drug Delivery System of Nifedipine for the Treatment of Preeclampsia. ( Avari, JG; Karemore, MN, 2019) |
| "A total of 626 patients with preeclampsia were enrolled, screened, and assigned by random to groups receiving either nifedipine + placebo or nifedipine + celastrol orally." | 2.84 | Celastrol synergizes with oral nifedipine to attenuate hypertension in preeclampsia: a randomized, placebo-controlled, and double blinded trial. ( Liang, Y; Wang, D; Xiao, S; Zhang, M, 2017) |
| "One hundred forty-eight women with mild preeclampsia were randomly allocated to treatment with either bed rest alone (n=64) or in combination with nifedipine (n=84) at 26-36 weeks' gestation." | 2.68 | The effect of nifedipine on urinary excretion of calcium in preeclampsia. ( Barton, JR; Mercer, BM; Sibai, BM, 1997) |
| "The patients with preeclampsia undergoing emergent cesarean section is always a challenge to an anesthesiologist, because severe hypertensive response after laryngoscopy and tracheal intubation may result in life-threatening complication such as cerebral hemorrhage." | 2.67 | [Nifedipine in preeclampsia for cesarean section]. ( Chen, JC; Hong, YJ; Lin, CF; Pan, P; Wei, TT; Wong, KL, 1993) |
| "Nifedipine is a calcium channel blocker that reduces blood pressure and increases renal blood flow." | 2.67 | The use of nifedipine during the postpartum period in patients with severe preeclampsia. ( Barton, JR; Conover, WB; Hiett, AK, 1990) |
| "Normal pregnancy is a complex and dynamic process that requires significant adaptation from the maternal system." | 2.66 | Hemodynamic Complications in Pregnancy: Preeclampsia and Beyond. ( Doherty, A; Kingdom, JC; McLaughlin, K, 2020) |
| "Pregnancy-induced hypertension is a major cause of maternal and fetal morbidity and mortality." | 2.61 | Hypertension and Pregnancy: Management and Future Risks. ( Jim, B; Reddy, S, 2019) |
| "Risk factors for the development of preeclampsia include microvascular diseases, such as diabetes mellitus; vascular and connective tissue disorders; hypertension; antiphospholipid antibody syndrome; and nephropathy." | 2.45 | Pharmacotherapeutic options for the treatment of preeclampsia. ( Baldwin, K; McCoy, S, 2009) |
| "Hypertension that complicates preeclampsia in pregnancy is a disorder that requires special consideration in both prevention and pharmacologic treatment." | 2.43 | Pathophysiology and medical management of systemic hypertension in preeclampsia. ( Frishman, WH; Schlocker, SJ; Tejani, N; Veresh, M, 2006) |
| "While nitroprusside is commonly used to treat severe hypertension, it is an extremely toxic drug that should only be used in rare circumstances." | 2.41 | The diagnosis and management of hypertensive crises. ( Marik, PE; Varon, J, 2000) |
| "We still do not have an ideal drug to treat acute severe hypertension in pregnancy." | 2.40 | Management of acute severe hypertension and encephalopathy. ( Mabie, WC, 1999) |
| "A review of the pathophysiology and treatment of pre-eclampsia indicates that vasospasm and vascular hyperreactivity are important elements in the disease process and its control." | 2.36 | Possible treatment of pre-eclampsia with calcium channel blocking agents. ( Zaret, GM, 1983) |
| " Therapy success: systolic blood pressure ~140 mm Hg and diastolic blood pressure ~90 mm Hg, therapy failure: persistent systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 110 mm Hg after maximum dosage of therapy (EL)." | 1.91 | Comparison of outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine in 355 pregnant Han Chinese women with preeclampsia. ( Dong, W; Peng, Z; Xiao, Y; Zhang, J, 2023) |
| "The HDP spectrum includes gestational hypertension (HTN), preeclampsia, eclampsia, HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, chronic HTN, and chronic HTN with superimposed preeclampsia." | 1.72 | Hypertensive Conditions: Hypertensive Disorders in Pregnancy. ( Daly, PL; Goodwin, ET; Kipnis, CM; Smith, DK, 2022) |
| "To explore the regulatory effect of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia." | 1.56 | Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia. ( Wang, DJ; Wu, Y; Zhang, R; Zhang, Y; Zhang, YX, 2020) |
| "Preeclampsia is characterised by systemic endothelial cell dysfunction thought to be triggered by toxic/dangerous factors from the placenta, including placental extracellular vesicles (EVs)." | 1.46 | Treating normal early gestation placentae with preeclamptic sera produces extracellular micro and nano vesicles that activate endothelial cells. ( Chamley, LW; Chen, Q; Stone, PR; Tong, M; Wise, MR; Xiao, F; Xiao, X; Zhao, M, 2017) |
| "In 14 patients with preeclampsia, 55 hypertensive emergencies were identified (BP >150/95)." | 1.46 | A trial of oral nifedipine and oral labetalol in preeclampsia hypertensive emergency treatment. ( Arjona-Berral, JE; Castelo-Branco, C; Duro-Gómez, J; Duro-Gómez, L; Giménez de Azcárete, M; Hernández-Angeles, C; Rodríguez-Marín, AB, 2017) |
| "Women with preeclampsia have elevated levels of inflammatory cytokines including IL-6." | 1.42 | The reduction of circulating levels of IL-6 in pregnant women with preeclampsia by magnesium sulphate and nifedipine: In vitro evidence for potential mechanisms. ( Chamley, LW; Chen, Q; Guo, F; Stone, PR; Xiao, JP; Yin, YX; Zhao, M, 2015) |
| "Totally 704 preeclampsia patients were randomly assigned to the treatment group and the control group, 352 cases in each group." | 1.42 | [Effect of Magnesium Sulfate, Nifedipine Tablet Combined Salvia Injection on ET-1/NO, TXA2/PGI2 and Hemorheology of Preeclampsia Patients]. ( Li, M; Qiu, SQ; Yao, J; Zhang, M; Zheng, XY; Zhu, JM; Zhu, ZX, 2015) |
| "Mean ± SD ZFP was lower in women with preeclampsia than in controls (16." | 1.40 | Cerebral perfusion pressure in women with preeclampsia is elevated even after treatment of elevated blood pressure. ( Brussé, IA; Duvekot, JJ; Grune, F; Sonneveld, MJ; Steegers, EA; Visser, GH, 2014) |
| "Takayasu's arteritis is a chronic and non-specific disease of young women in reproductive age that primarily affects the aorta, its branches and the pulmonary artery." | 1.37 | [Takayasu's arteritis in pregnancy: report seven cases]. ( Carvajal-Valencia, JA; Chacón-Solís, AR; Estrada-Altamirano, A; Hernández-Pacheco, JA; Maya-Quiñones, JL; Valenzuela-Jirón, A, 2011) |
| "Subsequently preeclampsia developed and uteroplacental dysfunction deteriorated." | 1.34 | Severe, early-onset hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome episode with spontaneous remission during pregnancy. ( Gembruch, U; Merz, WM, 2007) |
| "Levcromakalim has a vasodilatory effect on the umbilical artery like magnesium sulphate and nifedipine, and serves as an antihypertensive potential that might be used in the treatment of preeclampsia." | 1.34 | Vasorelaxant effect of levcromakalim on isolated umbilical arteries of preeclamptic women. ( Danisman, N; Polat, B; Tufan, H, 2007) |
| "The cases had more severe preeclampsia and a longer magnesium sulfate infusion." | 1.33 | Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. ( Carleton, B; Cheng, C; Côté, AM; Ensom, MH; Li, J; Magee, LA; Miremadi, S; von Dadelszen, P, 2005) |
| "To investigate whether women with preeclampsia and abnormal liver function tests have raised serum bile acids." | 1.32 | Preeclampsia with abnormal liver function tests is associated with cholestasis in a subgroup of cases. ( de Swiet, M; Goulis, DG; Redman, CW; Walker, IA; Williamson, C, 2004) |
| "Also, patients with superimposed preeclampsia were treated with 40 mg/day oral nifedipine." | 1.28 | Nifedipine treatment in preeclampsia reverts the increased erythrocyte aggregation to normal. ( Boemi, M; De Tommaso, G; Fumelli, P; Garzetti, GG; Lucino, E; Romanini, C; Tranquilli, AL, 1992) |
| "Pharmacokinetic and pharmacodynamic parameters of oral nifedipine were studied in the immediate postpartum period in eight women with preeclampsia." | 1.28 | Nifedipine pharmacokinetics and pharmacodynamics during the immediate postpartum period in patients with preeclampsia. ( Barton, JR; Prevost, RR; Sibai, BM; Whybrew, WD; Wilson, DA, 1991) |
| "Twenty patients with preeclampsia at a gestational age of 26 to 35 weeks were treated with oral nifedipine until delivery." | 1.28 | The effect of nifedipine therapy on fetal and placental Doppler waveforms in preeclampsia remote from term. ( Akl, S; Fairlie, FM; Khoury, AD; Moretti, MM; Sibai, BM, 1990) |
| "Two women with preeclampsia treated unsuccessfully with alpha-methyldopa and magnesium sulfate became profoundly hypotensive when oral nifedipine was added." | 1.27 | Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia? ( Cámera, MI; Martinotti, A; Mayorga, LM; Vignolo, CA; Waisman, GD, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (9.80) | 18.7374 |
| 1990's | 32 (31.37) | 18.2507 |
| 2000's | 19 (18.63) | 29.6817 |
| 2010's | 25 (24.51) | 24.3611 |
| 2020's | 16 (15.69) | 2.80 |
| Authors | Studies |
|---|---|
| Bastian, IN | 1 |
| Antony, KM | 1 |
| Cleary, EM | 1 |
| Racchi, NW | 1 |
| Patton, KG | 1 |
| Kudrimoti, M | 1 |
| Costantine, MM | 1 |
| Rood, KM | 1 |
| Kipnis, CM | 1 |
| Daly, PL | 1 |
| Goodwin, ET | 1 |
| Smith, DK | 1 |
| Karadas, B | 2 |
| Acar-Sahan, S | 2 |
| Kantarci, S | 2 |
| Uysal, N | 2 |
| Horoz, E | 2 |
| Kaya-Temiz, T | 2 |
| S, D | 1 |
| Novri, DA | 1 |
| Hamidy, Y | 1 |
| Savira, M | 1 |
| Bajpai, D | 1 |
| Popa, C | 1 |
| Verma, P | 1 |
| Dumanski, S | 1 |
| Shah, S | 1 |
| Ashworth, D | 1 |
| Battersby, C | 1 |
| Bick, D | 1 |
| Green, M | 1 |
| Hardy, P | 1 |
| Leighton, L | 1 |
| Magee, LA | 2 |
| Maher, A | 1 |
| McManus, RJ | 1 |
| Moakes, C | 1 |
| Morris, RK | 1 |
| Nelson-Piercy, C | 3 |
| Sparkes, J | 1 |
| Rivero-Arias, O | 1 |
| Webb, A | 1 |
| Wilson, H | 1 |
| Myers, J | 1 |
| Chappell, LC | 3 |
| Bhat, AD | 1 |
| Keasler, PM | 1 |
| Kolluru, L | 1 |
| Dombrowski, MM | 1 |
| Palanisamy, A | 1 |
| Singh, PM | 1 |
| Peng, Z | 1 |
| Zhang, J | 1 |
| Xiao, Y | 1 |
| Dong, W | 1 |
| Webster, LM | 2 |
| Reed, K | 1 |
| Myers, JE | 2 |
| Burns, A | 1 |
| Gupta, P | 1 |
| Patel, P | 1 |
| Wiesender, C | 1 |
| Seed, PT | 2 |
| Saade, GR | 2 |
| Mol, BW | 1 |
| Kantorowska, A | 1 |
| Heiselman, CJ | 1 |
| Halpern, TA | 1 |
| Akerman, MB | 1 |
| Elsayad, A | 1 |
| Muscat, JC | 1 |
| Sicuranza, GB | 1 |
| Vintzileos, AM | 1 |
| Heo, HJ | 1 |
| Rezk, M | 1 |
| Bellos, I | 1 |
| Pergialiotis, V | 1 |
| Papapanagiotou, A | 1 |
| Loutradis, D | 1 |
| Daskalakis, G | 1 |
| Wu, Y | 1 |
| Wang, DJ | 1 |
| Zhang, Y | 1 |
| Zhang, YX | 1 |
| Zhang, R | 1 |
| Doherty, A | 1 |
| McLaughlin, K | 1 |
| Kingdom, JC | 1 |
| Mulder, EG | 1 |
| Ghossein-Doha, C | 1 |
| Cauffman, E | 1 |
| Lopes van Balen, VA | 1 |
| Schiffer, VMMM | 1 |
| Alers, RJ | 1 |
| Oben, J | 1 |
| Smits, L | 1 |
| van Kuijk, SMJ | 1 |
| Spaanderman, MEA | 1 |
| Xiao, X | 1 |
| Xiao, F | 1 |
| Zhao, M | 2 |
| Tong, M | 1 |
| Wise, MR | 1 |
| Stone, PR | 3 |
| Chamley, LW | 3 |
| Chen, Q | 3 |
| Duro-Gómez, J | 1 |
| Rodríguez-Marín, AB | 1 |
| Giménez de Azcárete, M | 1 |
| Duro-Gómez, L | 1 |
| Hernández-Angeles, C | 1 |
| Arjona-Berral, JE | 1 |
| Castelo-Branco, C | 1 |
| Shi, DD | 2 |
| Guo, JJ | 1 |
| Zhou, L | 2 |
| Wang, N | 2 |
| Xiao, S | 1 |
| Zhang, M | 3 |
| Liang, Y | 1 |
| Wang, D | 1 |
| Wang, Y | 1 |
| Shi, D | 1 |
| Chen, L | 1 |
| Mills, C | 1 |
| Watt-Coote, I | 1 |
| Khalil, A | 1 |
| Cruickshank, JK | 1 |
| Watson, K | 1 |
| Broscious, R | 1 |
| Devabhakthuni, S | 1 |
| Noel, ZR | 1 |
| Gainder, S | 1 |
| Thakur, M | 1 |
| Saha, SC | 1 |
| Prakash, M | 1 |
| Reddy, S | 1 |
| Jim, B | 1 |
| Karemore, MN | 1 |
| Avari, JG | 1 |
| Feng, H | 1 |
| Alexander, JM | 1 |
| Wilson, KL | 1 |
| Arulkumaran, N | 1 |
| Lightstone, L | 1 |
| Sonneveld, MJ | 1 |
| Brussé, IA | 1 |
| Duvekot, JJ | 1 |
| Steegers, EA | 1 |
| Grune, F | 1 |
| Visser, GH | 1 |
| Vadhera, RB | 1 |
| Simon, M | 1 |
| Guo, F | 2 |
| Yin, YX | 1 |
| Xiao, JP | 1 |
| Zheng, XY | 1 |
| Yao, J | 1 |
| Zhu, JM | 1 |
| Li, M | 1 |
| Qiu, SQ | 1 |
| Zhu, ZX | 1 |
| Olson-Chen, C | 1 |
| Seligman, NS | 1 |
| Richter, AE | 1 |
| Schat, TE | 1 |
| Van Braeckel, KN | 1 |
| Scherjon, SA | 1 |
| Bos, AF | 1 |
| Kooi, EM | 1 |
| Yang, FZ | 1 |
| Veena, P | 1 |
| Perivela, L | 1 |
| Raghavan, SS | 1 |
| McCoy, S | 1 |
| Baldwin, K | 1 |
| Liu, Z | 1 |
| Wang, XY | 1 |
| Yan, NN | 1 |
| Hernández-Pacheco, JA | 1 |
| Estrada-Altamirano, A | 1 |
| Valenzuela-Jirón, A | 1 |
| Maya-Quiñones, JL | 1 |
| Carvajal-Valencia, JA | 1 |
| Chacón-Solís, AR | 1 |
| Liu, S | 1 |
| Xiao, J | 1 |
| Wang, C | 1 |
| Snowise, S | 1 |
| Liu, QQ | 1 |
| Yu, YH | 1 |
| Gong, SP | 1 |
| Huang, LP | 1 |
| Greene, MF | 1 |
| Belfort, MA | 1 |
| Anthony, J | 1 |
| Allen, JC | 1 |
| Goulis, DG | 1 |
| Walker, IA | 1 |
| de Swiet, M | 1 |
| Redman, CW | 2 |
| Williamson, C | 1 |
| Auger, K | 1 |
| Beauséjour, A | 1 |
| Brochu, M | 1 |
| St-Louis, J | 1 |
| Houlihan, DD | 1 |
| Dennedy, MC | 1 |
| Ravikumar, N | 1 |
| Morrison, JJ | 1 |
| Wong, AY | 1 |
| Chan, RS | 1 |
| Irwin, MG | 1 |
| Miremadi, S | 1 |
| Li, J | 1 |
| Cheng, C | 1 |
| Ensom, MH | 1 |
| Carleton, B | 1 |
| Côté, AM | 1 |
| von Dadelszen, P | 1 |
| Frishman, WH | 1 |
| Veresh, M | 1 |
| Schlocker, SJ | 1 |
| Tejani, N | 1 |
| Polat, B | 1 |
| Tufan, H | 1 |
| Danisman, N | 1 |
| Merz, WM | 1 |
| Gembruch, U | 1 |
| Manzur-Verástegui, S | 1 |
| Mandeville, PB | 1 |
| Gordillo-Moscoso, A | 1 |
| Hernández-Sierra, JF | 1 |
| Rodríguez-Martínez, M | 1 |
| Zaret, GM | 1 |
| Altura, BM | 1 |
| Altura, BT | 1 |
| Visser, W | 1 |
| Wallenburg, HC | 1 |
| Levin, AC | 1 |
| Doering, PL | 1 |
| Hatton, RC | 1 |
| Hata, T | 1 |
| Manabe, A | 1 |
| Hata, K | 1 |
| Kitao, M | 1 |
| Caruso, A | 1 |
| Ferrazzani, S | 1 |
| De Carolis, S | 1 |
| Romano, D | 1 |
| Mancinelli, S | 1 |
| De Carolis, MP | 1 |
| Connelly, JF | 1 |
| Hong, YJ | 1 |
| Lin, CF | 1 |
| Chen, JC | 1 |
| Pan, P | 1 |
| Wong, KL | 1 |
| Wei, TT | 1 |
| Ismail, AA | 1 |
| Medhat, I | 1 |
| Tawfic, TA | 1 |
| Kholeif, A | 1 |
| Walss Rodriguez, RJ | 3 |
| Flores Padilla, LM | 1 |
| Scardo, JA | 3 |
| Vermillion, ST | 3 |
| Hogg, BB | 2 |
| Newman, RB | 3 |
| Benedetto, C | 1 |
| Zonca, M | 1 |
| Giarola, M | 1 |
| Maulà, V | 1 |
| Chiarolini, L | 1 |
| Carandente, F | 1 |
| Brown, MA | 1 |
| McCowan, LM | 1 |
| North, RA | 1 |
| Walters, BN | 1 |
| Hao, C | 1 |
| Yu, X | 1 |
| Li, F | 1 |
| Idama, TO | 1 |
| Lindow, SW | 1 |
| Barton, JR | 4 |
| Mercer, BM | 2 |
| Sibai, BM | 4 |
| Kwawukume, EY | 1 |
| Ghosh, TS | 1 |
| Mabie, WC | 1 |
| Chauhan, SP | 2 |
| Hall, DR | 3 |
| Odendaal, HJ | 3 |
| Steyn, DW | 2 |
| Smith, M | 1 |
| Varon, J | 1 |
| Marik, PE | 1 |
| Grové, D | 2 |
| Kirsten, GF | 1 |
| Smith, J | 1 |
| Hussein, M | 1 |
| Mooij, JM | 1 |
| Roujouleh, H | 1 |
| Wang, Z | 1 |
| Song, H | 1 |
| Aali, BS | 1 |
| Nejad, SS | 1 |
| Cong, KJ | 1 |
| Akl, S | 2 |
| Sarinoglu, C | 1 |
| Tranquilli, AL | 1 |
| Garzetti, GG | 1 |
| De Tommaso, G | 1 |
| Boemi, M | 1 |
| Lucino, E | 1 |
| Fumelli, P | 1 |
| Romanini, C | 1 |
| Furuhashi, N | 2 |
| Tsujiei, M | 2 |
| Kimura, H | 2 |
| Nagae, H | 1 |
| Yajima, A | 2 |
| Hironaka, K | 1 |
| Makino, H | 1 |
| Kumagai, I | 1 |
| Haramoto, T | 1 |
| Yamasaki, Y | 1 |
| Shikata, K | 1 |
| Takahashi, M | 1 |
| Nishii, M | 1 |
| Ota, Z | 1 |
| Villarreal Ordaz, F | 1 |
| Madrid Dominguez, RE | 1 |
| Prevost, RR | 1 |
| Wilson, DA | 1 |
| Whybrew, WD | 1 |
| Fenakel, K | 1 |
| Fenakel, G | 1 |
| Appelman, Z | 1 |
| Lurie, S | 1 |
| Katz, Z | 1 |
| Shoham, Z | 1 |
| Moretti, MM | 1 |
| Fairlie, FM | 1 |
| Khoury, AD | 1 |
| Ales, K | 1 |
| Hiett, AK | 1 |
| Conover, WB | 1 |
| Hanretty, KP | 1 |
| Whittle, MJ | 1 |
| Howie, CA | 1 |
| Rubin, PC | 3 |
| Naden, RP | 1 |
| Grabensee, B | 1 |
| Horn, L | 1 |
| Butters, L | 1 |
| McCabe, R | 1 |
| Waisman, GD | 1 |
| Mayorga, LM | 1 |
| Cámera, MI | 1 |
| Vignolo, CA | 1 |
| Martinotti, A | 1 |
| Norris, MC | 1 |
| Rose, JC | 1 |
| Dewan, DM | 1 |
| Papi, L | 1 |
| Giustarini, C | 1 |
| Filice, M | 1 |
| Ballestra, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor[NCT04392375] | Phase 4 | 110 participants (Actual) | Interventional | 2020-06-09 | Completed | ||
| Early Vascular Adjustments to Prevent Preeclampsia and Related Complications[NCT04216706] | 314 participants (Actual) | Observational | 2014-11-01 | Completed | |||
| Use of Sildenafil Citrate in Management of Mild Pre-eclampsia: A Randomized Controlled Trial[NCT03262961] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2016-09-15 | Recruiting | ||
| Lasix for the Prevention of De Novo Postpartum Hypertension: A Randomized Controlled Trial (LAPP Trial)[NCT04752475] | Phase 3 | 82 participants (Actual) | Interventional | 2021-10-20 | Completed | ||
| Postpartum Management of Gestational Hypertensive Disorders Using Furosemide: A Randomized Controlled Trial[NCT04343235] | Phase 4 | 13 participants (Actual) | Interventional | 2020-05-01 | Terminated (stopped due to Challenges with enrollment; primary investigator left the institution) | ||
| Labetalol Versus MgSO4 for the Prevention of Eclampsia Trial (LAMPET)[NCT00293735] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2015-06-30 | Withdrawn (stopped due to Lack of funding) | ||
| A Novel Protocol for Postpartum Magnesium Sulfate in Severe Preeclampsia When the Woman Received Less That 8 Hours Before Delivery. Six Versus Twenty-four Hours Postpartum[NCT02317146] | Phase 2/Phase 3 | 280 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia Receiving Treatment for More Than 8 Hours Before Delivery. A Randomized Multicenter Clinical Trial .[NCT02307201] | Phase 2/Phase 3 | 1,114 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| A Comparison of Fetal Hemodynamic Measurements Between Pregnant Women Taking Anti-hypertensive Medication and Controls[NCT00759278] | 0 participants (Actual) | Observational | 2008-08-31 | Withdrawn (stopped due to No participants) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT04392375)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Nifedipine 30MG | 20 |
| Placebo | 19 |
(NCT04392375)
Timeframe: Between enrollment and delivery, assessed up to 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Nifedipine 30MG | 8 |
| Placebo | 6 |
Measured acute antihypertension therapy between enrollment and delivery (NCT04392375)
Timeframe: Between enrollment and delivery, assessed up to 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Nifedipine 30MG | 18 |
| Placebo | 27 |
(NCT04392375)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Cesarean Delivery | Vaginal Delivery | |
| Nifedipine 30MG | 11 | 42 |
| Placebo | 17 | 32 |
Some participants could have more than one indication for Cesarean Delivery. (NCT04392375)
Timeframe: Between enrollment and delivery, assessed up to 18 weeks
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| First stage arrest | Second stage arrest | Nonreassuring fetal status | Worsening maternal status | |
| Nifedipine 30MG | 8 | 1 | 3 | 2 |
| Placebo | 6 | 5 | 7 | 1 |
Difference in MAP averaged over the 24 hours prior to discharge or the 24 hours prior to antihypertensive therapy initiation (whichever occurs first) (NCT04752475)
Timeframe: 24 hours prior to discharge through discharge, up to 7 days
| Intervention | mmHg (Mean) |
|---|---|
| Lasix (Furosemide) | 88.9 |
| Placebo | 86.8 |
breastfeeding continuation after discharge (NCT04343235)
Timeframe: at 1 week postpartum visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Labetalol + Furosemide | 1 |
| Labetalol Only | 3 |
number of patients who require a change in the dose of labetalol to control BP (NCT04343235)
Timeframe: Change in dose of hypertensive therapy from randomization until hospital discharge (up to 7 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Labetalol + Furosemide | 3 |
| Labetalol Only | 0 |
days in hospital after delivery (NCT04343235)
Timeframe: Number of days of hospital stay from randomization to discharge
| Intervention | days (Mean) |
|---|---|
| Labetalol + Furosemide | 3.5 |
| Labetalol Only | 4.3 |
readmission for hypertension management (NCT04343235)
Timeframe: up to 14 days after discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Labetalol + Furosemide | 1 |
| Labetalol Only | 2 |
average diastolic blood pressure reading on Day 0, Day 1, and Day 2 (NCT04343235)
Timeframe: Average diastolic blood pressure on Day 0, Day 1, and Day 2
| Intervention | mm of mercury (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 2 | |
| Labetalol + Furosemide | 84.1 | 81.8 | 78.8 |
| Labetalol Only | 80.1 | 80.7 | 75.5 |
average mean arterial pressure reading on Day 0, Day 1, and Day 2 (NCT04343235)
Timeframe: Average mean arterial pressure on Day 0, Day 1, and Day 2
| Intervention | mm of mercury (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 2 | |
| Labetalol + Furosemide | 102.4 | 99.5 | 98.0 |
| Labetalol Only | 100.0 | 100.1 | 96.0 |
average systolic blood pressure reading on Day 0, Day 1, and Day 2 (NCT04343235)
Timeframe: Average systolic blood pressure for Day 0, Day 1, and Day 2
| Intervention | mm of mercury (Mean) | ||
|---|---|---|---|
| Day 0 | Day 1 | Day 2 | |
| Labetalol + Furosemide | 138.4 | 134.9 | 135.2 |
| Labetalol Only | 138.1 | 138.2 | 136.7 |
21 reviews available for nifedipine and Pre-Eclampsia
| Article | Year |
|---|---|
Evaluation and Management of Hypertensive Disorders of Pregnancy.
Topics: Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn; Labetalol | 2023 |
Treatment of acute-onset hypertension in pregnancy: A network meta-analysis of randomized controlled trials comparing anti-hypertensives and route of administration.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Female; Humans; Hydralazine; Hypertension; Infant | 2023 |
Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis.
Topics: Abruptio Placentae; Amlodipine; Antihypertensive Agents; Atenolol; Cesarean Section; Chronic Disease | 2020 |
Hemodynamic Complications in Pregnancy: Preeclampsia and Beyond.
Topics: Anticonvulsants; Antihypertensive Agents; Aspirin; Delivery, Obstetric; Female; Fetal Growth Retarda | 2020 |
Focused Update on Pharmacologic Management of Hypertensive Emergencies.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Brain Ischemia; Emergencies; Enalapri | 2018 |
Hypertension and Pregnancy: Management and Future Risks.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Chronic Disease; Diuretics; Female; Human | 2019 |
Hypertensive emergencies of pregnancy.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Creatine; Diuretics; Emergency Medicine; Female; | 2013 |
Severe pre-eclampsia and hypertensive crises.
Topics: Administration, Intravenous; Administration, Oral; Antihypertensive Agents; Critical Care; Early Dia | 2013 |
Hypertensive emergencies in pregnancy.
Topics: Antihypertensive Agents; Eclampsia; Emergencies; Female; Humans; Hydralazine; Hypertension; Hyperten | 2014 |
Hypertensive Emergencies in Pregnancy.
Topics: Antihypertensive Agents; Cesarean Section; Chronic Disease; Congenital Abnormalities; Emergencies; E | 2016 |
Pharmacotherapeutic options for the treatment of preeclampsia.
Topics: Female; Humans; Hydralazine; Magnesium Sulfate; Nicardipine; Nifedipine; Nitroprusside; Pre-Eclampsi | 2009 |
[Clinical efficacy and perinatal outcome of nifedipine for severe preeclampsia: meta-analysis].
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Infant, Newborn; | 2012 |
Pathophysiology and medical management of systemic hypertension in preeclampsia.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium; Calcium Channel Blockers; Cerebral Hemorrhage; Female | 2006 |
Possible treatment of pre-eclampsia with calcium channel blocking agents.
Topics: Calcium Channel Blockers; Eclampsia; Female; Fetus; Humans; Hypertension; Nifedipine; Placenta; Pre- | 1983 |
Microcirculatory actions and uses of naturally-occurring (magnesium) and novel synthetic calcium channel blockers.
Topics: Anesthesia; Animals; Arterioles; Blood Pressure; Calcium; Calcium Channel Blockers; Cell Membrane Pe | 1984 |
Use of nifedipine in the hypertensive diseases of pregnancy.
Topics: Female; Humans; Hydralazine; Hypertension; Nifedipine; Pre-Eclampsia; Pregnancy; Pregnancy Complicat | 1994 |
Antihypertensive drugs of choice for treating preeclampsia.
Topics: Antihypertensive Agents; Female; Fetal Distress; Humans; Labetalol; Nifedipine; Pre-Eclampsia; Pregn | 1994 |
Magnesium sulphate: a review of clinical pharmacology applied to obstetrics.
Topics: Anesthesia, Obstetrical; Anticonvulsants; Breast Feeding; Calcium Channel Blockers; Cerebrovascular | 1998 |
Management of acute severe hypertension and encephalopathy.
Topics: Acute Disease; Antihypertensive Agents; Brain Diseases; Female; Humans; Hypertension; Nifedipine; Ni | 1999 |
The diagnosis and management of hypertensive crises.
Topics: Antihypertensive Agents; Aortic Aneurysm; Aortic Dissection; Clonidine; Diazoxide; Enalaprilat; Fema | 2000 |
Antihypertensive drugs in pregnancy.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Diazoxide; Diuretics; Female; Fetus; Humans; H | 1985 |
31 trials available for nifedipine and Pre-Eclampsia
| Article | Year |
|---|---|
Trial of Intrapartum Extended-Release Nifedipine to Prevent Severe Hypertension Among Pregnant Individuals With Preeclampsia With Severe Features.
Topics: Blood Pressure; Female; Humans; Hypertension; Infant, Newborn; Nifedipine; Pre-Eclampsia; Pregnancy | 2023 |
Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial.
Topics: Antihypertensive Agents; Female; Humans; Hydralazine; Labetalol; Nifedipine; Pre-Eclampsia; Pregnanc | 2022 |
A treatment strategy with nifedipine versus labetalol for women with pregnancy hypertension: study protocol for a randomised controlled trial (Giant PANDA).
Topics: Animals; Antihypertensive Agents; Female; Humans; Hypertension; Infant; Infant, Newborn; Labetalol; | 2023 |
Quantifying adherence to antihypertensive medication for chronic hypertension during pregnancy.
Topics: Adult; Antihypertensive Agents; Blood Pressure Determination; Chromatography, High Pressure Liquid; | 2019 |
Epigallocatechin gallate enhances treatment efficacy of oral nifedipine against pregnancy-induced severe pre-eclampsia: A double-blind, randomized and placebo-controlled clinical study.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Catechin; Double-Blind Method; | 2018 |
Celastrol synergizes with oral nifedipine to attenuate hypertension in preeclampsia: a randomized, placebo-controlled, and double blinded trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Drug | 2017 |
Lipid profile and cytokines in hypertension of pregnancy: A comparison of preeclampsia therapies.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cytokines; Double-Blind Method; Drug Administration | 2018 |
Longitudinal changes in vascular function parameters in pregnant women with chronic hypertension and association with adverse outcome: a cohort study.
Topics: Adult; Antihypertensive Agents; Birth Weight; Black People; Blood Pressure; Chronic Disease; Cohort | 2019 |
To study the changes in fetal hemodynamics with intravenous labetalol or nifedipine in acute severe hypertension.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; F | 2019 |
Formulation, Optimization, and In vivo Evaluation of Gastroretentive Drug Delivery System of Nifedipine for the Treatment of Preeclampsia.
Topics: Adult; Biological Availability; Chemistry, Pharmaceutical; Cross-Over Studies; Delayed-Action Prepar | 2019 |
Phytosterol enhances oral nifedipine treatment in pregnancy-induced preeclampsia: A placebo-controlled, double-blinded, randomized clinical trial.
Topics: Administration, Oral; Adult; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; | 2019 |
Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; D | 2016 |
Furosemide in postpartum management of severe preeclampsia: A randomized controlled trial.
Topics: Adult; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Ni | 2017 |
Furosemide in postpartum management of severe preeclampsia: A randomized controlled trial.
Topics: Adult; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Ni | 2017 |
Furosemide in postpartum management of severe preeclampsia: A randomized controlled trial.
Topics: Adult; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Ni | 2017 |
Furosemide in postpartum management of severe preeclampsia: A randomized controlled trial.
Topics: Adult; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Ni | 2017 |
[Treatment of albuminuria in gestational hypertension puerpera in the severe preeclampeia stage by TCM therapy for stasis-removing and diuresis].
Topics: Adult; Albuminuria; Diagnosis, Differential; Drug Therapy, Combination; Drugs, Chinese Herbal; Femal | 2009 |
A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia.
Topics: Anticonvulsants; Calcium Channel Blockers; Eclampsia; Female; Humans; Logistic Models; Magnesium Sul | 2003 |
A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia.
Topics: Anticonvulsants; Calcium Channel Blockers; Eclampsia; Female; Humans; Logistic Models; Magnesium Sul | 2003 |
A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia.
Topics: Anticonvulsants; Calcium Channel Blockers; Eclampsia; Female; Humans; Logistic Models; Magnesium Sul | 2003 |
A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia.
Topics: Anticonvulsants; Calcium Channel Blockers; Eclampsia; Female; Humans; Logistic Models; Magnesium Sul | 2003 |
A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia.
Topics: Anticonvulsants; Calcium Channel Blockers; Eclampsia; Female; Humans; Logistic Models; Magnesium Sul | 2003 |
A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia.
Topics: Anticonvulsants; Calcium Channel Blockers; Eclampsia; Female; Humans; Logistic Models; Magnesium Sul | 2003 |
A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia.
Topics: Anticonvulsants; Calcium Channel Blockers; Eclampsia; Female; Humans; Logistic Models; Magnesium Sul | 2003 |
A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia.
Topics: Anticonvulsants; Calcium Channel Blockers; Eclampsia; Female; Humans; Logistic Models; Magnesium Sul | 2003 |
A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia.
Topics: Anticonvulsants; Calcium Channel Blockers; Eclampsia; Female; Humans; Logistic Models; Magnesium Sul | 2003 |
Efficacy of nitroglycerine infusion versus sublingual nifedipine in severe pre-eclampsia: a randomized, triple-blind, controlled trial.
Topics: Administration, Sublingual; Adult; Female; Humans; Injections, Intravenous; Magnesium Sulfate; Nifed | 2008 |
A comparison between the haemodynamic effects of oral nifedipine and intravenous dihydralazine in patients with severe pre-eclampsia.
Topics: Administration, Oral; Antihypertensive Agents; Calcium Channel Blockers; Dihydralazine; Female; Hemo | 1995 |
[Nifedipine in preeclampsia for cesarean section].
Topics: Adult; Blood Pressure; Cesarean Section; Female; Humans; Nifedipine; Pre-Eclampsia; Pregnancy; Uteri | 1993 |
Evaluation of calcium-antagonist (Nifedipine) in the treatment of pre-eclampsia.
Topics: Adolescent; Adult; Female; Hemodynamics; Humans; Kidney Function Tests; Nifedipine; Pre-Eclampsia; P | 1993 |
[Management of severe pre-eclampsia/eclampsia. Comparison between nifedipine and hydralazine as antihypertensive agents].
Topics: Administration, Sublingual; Antihypertensive Agents; Apgar Score; Drug Evaluation; Eclampsia; Female | 1993 |
The effect of nifedipine on urinary excretion of calcium in preeclampsia.
Topics: Adolescent; Adult; Calcium; Calcium Channel Blockers; Female; Humans; Nifedipine; Pre-Eclampsia; Pre | 1997 |
Oral nifedipine therapy in the management of severe preeclampsia.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Female; Humans; Hydralazine; Infusions, Intrav | 1995 |
A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Blood Pressure; Calcium Channel Blockers; | 1999 |
A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; E | 1999 |
Nifedipine or prazosin as a second agent to control early severe hypertension in pregnancy: a randomised controlled trial.
Topics: Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hypertension; Ni | 2000 |
[Clinical observation on therapeutical effect of prepared rhubarb in treating pregnancy induced hypertension].
Topics: Adult; Antigen-Antibody Complex; CD4-CD8 Ratio; Drug Therapy, Combination; Female; Humans; Interleuk | 1999 |
Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia.
Topics: Adolescent; Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Nifedipine; | 2002 |
A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term.
Topics: Bed Rest; Blood Pressure; Female; Humans; Nifedipine; Pre-Eclampsia; Pregnancy; Pregnancy Outcome; P | 1992 |
[Management of severe pre-eclampsia in the puerperium. Comparative study of sublingual nifedipine and hydralazine].
Topics: Administration, Sublingual; Adolescent; Adult; Antihypertensive Agents; Female; Humans; Hydralazine; | 1991 |
Nifedipine in the treatment of severe preeclampsia.
Topics: Adult; Blood Pressure; Female; Humans; Hydralazine; Nifedipine; Pre-Eclampsia; Pregnancy; Pregnancy | 1991 |
The use of nifedipine during the postpartum period in patients with severe preeclampsia.
Topics: Blood Pressure; Diuresis; Female; Humans; Nifedipine; Postpartum Period; Pre-Eclampsia; Pregnancy; R | 1990 |
50 other studies available for nifedipine and Pre-Eclampsia
| Article | Year |
|---|---|
Gestational weight gain among gravidae with hypertension receiving labetalol versus nifedipine.
Topics: Antihypertensive Agents; Blood Pressure; Female; Gestational Weight Gain; Humans; Hypertension; Labe | 2022 |
Hypertensive Conditions: Hypertensive Disorders in Pregnancy.
Topics: Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Nifedipine; Pre | 2022 |
Comparison of relaxant effects of nifedipine and NS11021 on isolated umbilical arteries of healthy and preeclamptic pregnant women.
Topics: Female; Humans; Nifedipine; Pre-Eclampsia; Pregnancy; Pregnant Women; Umbilical Arteries; Vasodilato | 2023 |
Comparison of relaxant effects of nifedipine and NS11021 on isolated umbilical arteries of healthy and preeclamptic pregnant women.
Topics: Female; Humans; Nifedipine; Pre-Eclampsia; Pregnancy; Pregnant Women; Umbilical Arteries; Vasodilato | 2023 |
Comparison of relaxant effects of nifedipine and NS11021 on isolated umbilical arteries of healthy and preeclamptic pregnant women.
Topics: Female; Humans; Nifedipine; Pre-Eclampsia; Pregnancy; Pregnant Women; Umbilical Arteries; Vasodilato | 2023 |
Comparison of relaxant effects of nifedipine and NS11021 on isolated umbilical arteries of healthy and preeclamptic pregnant women.
Topics: Female; Humans; Nifedipine; Pre-Eclampsia; Pregnancy; Pregnant Women; Umbilical Arteries; Vasodilato | 2023 |
Comparison of outcomes following intravenous magnesium compared with intravenous labetalol and oral nifedipine in 355 pregnant Han Chinese women with preeclampsia.
Topics: Antihypertensive Agents; Blood Pressure; East Asian People; Female; Humans; Hypertension; Infant, Ne | 2023 |
Letter to the Editor regarding research integrity.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Methyldopa; Nifedipine; Pre-Eclampsia; Pregna | 2020 |
Identification of factors associated with delayed treatment of obstetric hypertensive emergencies.
Topics: Administration, Intravenous; Administration, Oral; Adult; After-Hours Care; Antihypertensive Agents; | 2020 |
Reply to letter regarding 'Methyldopa versus Nifedipine or no medication for treatment of chronic hypertension during pregnancy'.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Methyldopa; Nifedipine; Pre-Eclampsia; Pregna | 2020 |
Regulation of magnesium sulfate combined with nifedipine and labetalol on disease-related molecules in serum and placenta in the treatment of preeclampsia.
Topics: Administration, Oral; Adult; E-Selectin; Female; Humans; Labetalol; Magnesium Sulfate; Nifedipine; P | 2020 |
Preventing Recurrent Preeclampsia by Tailored Treatment of Nonphysiologic Hemodynamic Adjustments to Pregnancy.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Hemodynamics; Humans; Labetalol; Methyldopa; | 2021 |
Treating normal early gestation placentae with preeclamptic sera produces extracellular micro and nano vesicles that activate endothelial cells.
Topics: Cells, Cultured; Endothelial Cells; Extracellular Vesicles; Female; HMGB1 Protein; Humans; Immune Se | 2017 |
A trial of oral nifedipine and oral labetalol in preeclampsia hypertensive emergency treatment.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Administratio | 2017 |
Cerebral perfusion pressure in women with preeclampsia is elevated even after treatment of elevated blood pressure.
Topics: Adult; Antihypertensive Agents; Arterial Pressure; Blood Flow Velocity; Case-Control Studies; Cerebr | 2014 |
The reduction of circulating levels of IL-6 in pregnant women with preeclampsia by magnesium sulphate and nifedipine: In vitro evidence for potential mechanisms.
Topics: Adolescent; Adult; Endothelial Cells; Female; Humans; Interleukin-6; Magnesium Sulfate; Nifedipine; | 2015 |
[Effect of Magnesium Sulfate, Nifedipine Tablet Combined Salvia Injection on ET-1/NO, TXA2/PGI2 and Hemorheology of Preeclampsia Patients].
Topics: Drug Therapy, Combination; Drugs, Chinese Herbal; Endothelin-1; Epoprostenol; Female; Hemorheology; | 2015 |
The Effect of Maternal Antihypertensive Drugs on the Cerebral, Renal and Splanchnic Tissue Oxygen Extraction of Preterm Neonates.
Topics: Antihypertensive Agents; Brain; Cerebrovascular Circulation; Female; Gestational Age; Hemodynamics; | 2016 |
[Takayasu's arteritis in pregnancy: report seven cases].
Topics: Adult; Antihypertensive Agents; Cesarean Section; Female; Fetal Growth Retardation; Follow-Up Studie | 2011 |
Calcium channel blockers prevent endothelial cell activation in response to necrotic trophoblast debris: possible relevance to pre-eclampsia.
Topics: Adolescent; Adult; Calcium Channel Blockers; Case-Control Studies; Cell Adhesion; Cell Proliferation | 2012 |
Magnesium sulfate for preeclampsia.
Topics: Anticonvulsants; Eclampsia; Female; History, 17th Century; History, 18th Century; History, 20th Cent | 2003 |
Preeclampsia with abnormal liver function tests is associated with cholestasis in a subgroup of cases.
Topics: Adrenergic alpha-Agonists; Adult; Anti-Inflammatory Agents; Bile Acids and Salts; Biomarkers; Blood | 2004 |
Increased Na+ intake during gestation in rats is associated with enhanced vascular reactivity and alterations of K+ and Ca2+ function.
Topics: Animals; Aorta; Arginine Vasopressin; Blood Pressure; Calcium; Calcium Channel Blockers; Female; Mal | 2004 |
Anti-hypertensive therapy and the feto-placental circulation: effects on umbilical artery resistance.
Topics: Adult; Antihypertensive Agents; Dose-Response Relationship, Drug; Female; Fetus; Humans; Hydralazine | 2004 |
Anesthetic management of Cesarean delivery in a patient with hypoplastic anemia and severe pre-eclampsia.
Topics: Adult; Anemia, Hypoplastic, Congenital; Anesthesia, General; Anesthesia, Obstetrical; Blood Pressure | 2004 |
Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia.
Topics: Adult; Antihypertensive Agents; Calcium Channel Blockers; Case-Control Studies; Cohort Studies; Drug | 2005 |
Vasorelaxant effect of levcromakalim on isolated umbilical arteries of preeclamptic women.
Topics: Adult; Case-Control Studies; Cromakalim; Dose-Response Relationship, Drug; Female; Humans; In Vitro | 2007 |
Severe, early-onset hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome episode with spontaneous remission during pregnancy.
Topics: Adult; Antihypertensive Agents; Female; Fetal Death; HELLP Syndrome; Humans; Methyldopa; Nifedipine; | 2007 |
Changes in blood velocities of fetal circulation in association with fetal heart rate abnormalities: effect of sublingual administration of nifedipine.
Topics: Administration, Sublingual; Adult; Blood Flow Velocity; Female; Fetal Growth Retardation; Heart Rate | 1995 |
The use of nifedipine as first-line hypotensive therapy in gestational hypertension.
Topics: Adult; Female; Gestational Age; Humans; Hypertension; Infant, Newborn; Nifedipine; Pre-Eclampsia; Pr | 1994 |
Hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies.
Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Blood Pressure; Emergencies; Femal | 1996 |
24-hour blood pressure monitoring to evaluate the effects of nifedipine in pre-eclampsia and in chronic hypertension in pregnancy.
Topics: Adult; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Chronic Dise | 1997 |
Withdrawal of nifedipine capsules: jeopardizing the treatment of acute severe hypertension in pregnancy? Australasian Society for the Study of Hypertension in Pregnancy.
Topics: Antihypertensive Agents; Australia; Female; Humans; Legislation, Drug; Nifedipine; Pre-Eclampsia; Pr | 1997 |
[The effect of nifedipine on the microcirculation in pregnancy-induced hypertension].
Topics: Adult; Blood Pressure; Calcium Channel Blockers; Female; Humans; Microcirculation; Nails; Nifedipine | 1996 |
Expectant management of early onset, severe pre-eclampsia: maternal outcome.
Topics: Adolescent; Adult; Antihypertensive Agents; Calcium Channel Blockers; Dihydralazine; Female; Fetal D | 2000 |
Expectant management of early onset, severe pre-eclampsia: perinatal outcome.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Female; Fetal Monitoring; Humans; Infant Mortalit | 2000 |
Factor analysis, including antihypertensive medication, of the outcome of pregnancy in pregnancy-associated hypertension.
Topics: Antihypertensive Agents; Apgar Score; Cesarean Section; Comorbidity; Disease Susceptibility; Female; | 2001 |
[Hemodynamic effects of antihypertensive drugs on pregnancy-induced hypertension].
Topics: Antihypertensive Agents; Female; Hemodynamics; Humans; Nifedipine; Pre-Eclampsia; Pregnancy | 1992 |
Nifedipine treatment in preeclampsia reverts the increased erythrocyte aggregation to normal.
Topics: Erythrocyte Aggregation; Female; Humans; Nifedipine; Pre-Eclampsia; Pregnancy; Reference Values | 1992 |
Effects of nifedipine on placental blood flow, placental weight and fetal weight in normotensive and spontaneously hypertensive rats.
Topics: Animals; Female; Fetus; Nifedipine; Placenta; Pre-Eclampsia; Pregnancy; Pregnancy, Animal; Rats; Rat | 1992 |
A case of nephrotic syndrome and renal dysfunction in a pregnant woman with diabetes mellitus.
Topics: Adult; Basement Membrane; Biopsy; Calcium Channel Blockers; Capillaries; Diabetic Nephropathies; End | 1992 |
Effects of nifedipine on normotensive rat placental blood flow, placental weight and fetal weight.
Topics: Animals; Birth Weight; Blood Flow Velocity; Drug Evaluation, Preclinical; Electrolysis; Female; Fetu | 1991 |
[Effect of nifedipine on fetal heart rate in pre-eclamptic patients].
Topics: Adolescent; Adult; Female; Heart Rate, Fetal; Humans; Nifedipine; Pre-Eclampsia; Pregnancy | 1991 |
Nifedipine pharmacokinetics and pharmacodynamics during the immediate postpartum period in patients with preeclampsia.
Topics: Administration, Oral; Female; Half-Life; Humans; Nifedipine; Postpartum Period; Pre-Eclampsia; Pregn | 1991 |
The effect of nifedipine therapy on fetal and placental Doppler waveforms in preeclampsia remote from term.
Topics: Administration, Oral; Adolescent; Adult; Aorta; Blood Pressure; Carotid Artery, Internal; Female; Fe | 1990 |
Magnesium plus nifedipine.
Topics: Blood Pressure; Drug Interactions; Female; Humans; Magnesium; Nifedipine; Pre-Eclampsia; Pregnancy | 1990 |
Effect of nifedipine on Doppler flow velocity waveforms in severe pre-eclampsia.
Topics: Adult; Blood Flow Velocity; Female; Humans; Nifedipine; Placenta; Pre-Eclampsia; Pregnancy; Ultrason | 1989 |
[Therapy of the hypertensive crisis].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Calcium Channel Blockers; Clonidine; Dihydralazin | 1985 |
Preeclampsia: platelets and antiplatelet therapy.
Topics: Aspirin; Blood Coagulation; Blood Platelets; Diagnosis, Differential; Female; Fetus; Humans; Hyperte | 1988 |
Nifedipine and platelets in preeclampsia.
Topics: Blood Pressure; Female; Humans; Nifedipine; Platelet Count; Pre-Eclampsia; Pregnancy; Time Factors | 1988 |
Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia?
Topics: Adult; Drug Synergism; Female; Humans; Hypertension; Magnesium Sulfate; Methyldopa; Nifedipine; Pre- | 1988 |
Nifedipine or verapamil counteracts hypertension in gravid ewes.
Topics: Animals; Blood Gas Analysis; Female; Hypertension; Nifedipine; Norepinephrine; Pre-Eclampsia; Pregna | 1986 |
[Hypertensive crisis during E.P.H. gestosis treated with sublingual nifedipine. Report of a case].
Topics: Administration, Oral; Adolescent; Female; Humans; Hypertension; Nifedipine; Pre-Eclampsia; Pregnancy | 1985 |